Director of FP&A
PhantomSalary not specified
- Full Time
- Senior (5 to 8 years)
Not SpecifiedCompensation
Mid-level (3 to 4 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, PharmaceuticalsIndustries
Requirements
Candidates should possess a Bachelor’s degree in Finance, Accounting, Economics, or a related field, and ideally hold a Master’s degree. They should have at least 7 years of progressive experience in financial planning and analysis, with a minimum of 5 years in a leadership role within the pharmaceutical or biotechnology industry. Strong analytical and problem-solving skills are essential, along with proficiency in financial modeling and forecasting techniques.
Responsibilities
The Associate Director, Financial Planning & Analysis will lead the budget and headcount planning process, including annual planning, forecasting, and scenario analysis, in collaboration with business teams. They will partner with key business owners to manage the annual Budget/Reforecast, providing monthly financial reporting and analysis to support business decisions. This role will also support financial reporting for board meetings, executive reviews, and earnings releases, while developing and updating financial outlooks incorporating business trends. Furthermore, the Associate Director will proactively identify and implement processes to scale with company growth, develop reporting tools, and complete special projects as needed.
Skills
Budgeting
Forecasting
Variance Analysis
Financial Reporting
Scenario Analysis
Financial Modeling
Process Improvement
Corcept Therapeutics
Develops cortisol modulators for medical conditions
About Corcept Therapeutics
Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.
Key Metrics
Menlo Park, CaliforniaHeadquarters
1998Year Founded
$39.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees